# Patent

## Title
Vaccine composition comprising an immunogenic protein and combination adjuvants for use in eliciting antigen-specific T-cell responses

## Abstract

Vaccine compositions for use in inducing enhanced antigen-specific T cell-mediated immune responses in a subject in need thereof are disclosed. The composition comprises (a) a therapeutically effective amount of an immunogenic protein comprising at least an antigen of a pathogen; (b) a saponin-base adjuvant selected from the group consisting of GPI-0100, Quil A, QS-21; and (c) a Toll-like receptor (TLR) agonist adjuvant selected from the group consisting of monophosphoryl lipid A (MPL), and CpG1826.

## Background
REFERENCE TO RELATED APPLICATION
The present application claims the priority to U.S. Provisional Application Ser. No. 62/121,406, filed Feb. 26, 2015, which is herein incorporated by reference in its entirety.


FIELD OF THE INVENTION
The present invention relates generally to vaccine formulations, and more specifically to vaccine formulations with combination adjuvants.
BACKGROUND OF THE INVENTION
Adjuvants are critical components of many vaccines. The majority of existing vaccines contain a single adjuvant. Owing to their inherent limitations, no single adjuvant is capable of inducing all the protective immune responses required in the many different vaccines. Therefore, there is a need for exploring the potential of using formulations with multiple adjuvants in a vaccine.
SUMMARY OF THE INVENTION
In one aspect, the invention relates to a vaccine composition comprising:
(a) a therapeutically effective amount of an immunogenic protein comprising at least an antigen of a pathogen;
(b) a saponin-base adjuvant selected from the group consisting of GPI-0100, Quil A, QS-21; and
(c) a Toll-like receptor (TLR) agonist adjuvant selected from the group consisting of monophosphoryl lipid A (MPL), and CpG1826.
In another embodiment of the invention, the composition further comprises at least one additive selected from the group consisting of mannitol, sucrose, trehalose, histindine, glycine, arginine, sorbitol, Polysorbate 80, glucose, lactose, maltose, maltodextrins, citrate, Tris and sodium phosphate.
In another embodiment of the invention, the immunogenic protein is a fusion protein comprising:
(a) an antigen-presenting cell (APC)-binding domain or a CD91 receptor-binding domain, located at the N-terminus of the fusion protein;
(b) a protein transduction domain, located at the C-terminus of the APC-binding domain or the CD91 receptor-binding domain, the protein transduction domain being selected from the group consisting of:

    
    
        (i) a fusion polypeptide comprising:
        
            (1) a T cell sensitizing signal-transducing peptide consisting of 28-53 amino acid residues in length, comprising the amino acid sequence of SEQ ID NO: 31, in which Xaa8 is I or L; Xaa10 is V. F or A, Xaa11 is M or L, Xaa17 is L or I, being located at the N-terminus of the fusion polypeptide;
            (2) a translocation peptide consisting of 34-112 amino acid residues in length, comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 3, 20, 4, or 41; and
            (3) a linker, comprising SEQ ID NO: 15 linking the T cell sensitizing signal-transducing peptide and the translocation peptide;
        
        
        (ii) a T cell-sensitizing signal-transducing peptide consisting of 28-53 amino acid residues in length, comprising the amino acid sequence of SEQ ID NO: 31, in which Xaa8 is I or L; Xaa10 is V, F or A, Xaa11 is M or L, Xaa17 is L or I; and
        (iii) a translocation peptide of 34-61 amino acid residues in length, comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 3, 20, or 41; and
    
    


(c) an antigen of a pathogen, located at the C-terminus of the protein transduction domain;
wherein the APC-binding domain or the CD91 receptor-binding domain is free of the amino acid sequence of Pseudomonas exotoxin A (PE) binding domain Ia if the protein transduction domain is the translocation peptide in (biii).
In another embodiment of the invention, the protein transduction domain comprises the sequence of SEQ ID NO: 30.
In another embodiment of the invention, the APC-binding domain or the CD91 receptor-binding domain is a polypeptide comprising an amino acid sequence that is at least 90% identical to the sequence selected from the group consisting of SEQ ID NOs: 5, 9, 6, 7, and 8.
In another embodiment of the invention, the APC-binding domain or the CD91 receptor-binding domain comprises an amino acid sequence that is at least 95% identical to the sequence selected from the group consisting of SEQ ID NOs: 5, 9, 6, 7, and 8.
In another embodiment of the invention, the APC-binding domain or the CD91 receptor-binding domain is a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 5, 9, 6, 7, and 8.
Alternatively, the APC-binding domain is selected from the group consisting of receptor-associated protein-1 (RAP1) domain III, alpha-2-macroglobulin receptor-associated protein (A2M), HIV-Tat, and heat shock proteins (HSPs), and Pseudomonas exotoxin A (PE) binding domain Ia.
In another embodiment of the invention, the fusion protein is free of the amino acid sequence of Pseudomonas exotoxin A (PE) binding domain Ia.
In another embodiment of the invention, the fusion protein further comprises an endoplasmic reticulum retention sequence located at the C-terminus of the fusion protein.
In another embodiment of the invention, the endoplasmic reticulum (ER) retention sequence comprises the amino acid sequence of Lys-Asp-Glu-Leu (SEQ ID NO: 14). The ER retention sequence may comprise a sequence selected from the group consisting of SEQ ID NOs: 14, 16-19. Alternatively, the ER retention sequence may consist of a sequence selected from the group consisting of SEQ ID NOs: 16-19.
In another embodiment of the invention, the fusion protein is free of an endoplasmic reticulum retention sequence at C-terminus thereof if the antigen contains 10 or more epitopes.
In another embodiment of the invention, the protein transduction domain is the fusion polypeptide in (bi).
In another embodiment of the invention, the protein transduction domain is the T cell-sensitizing signal-transducing peptide in (bii).
In another embodiment of the invention, the fusion protein further comprises an additional linker between the protein transduction domain and the antigen, the additional linker comprising SEQ ID NO: 15.
In another embodiment of the invention, the protein transduction domain is the translocation peptide in (biii).
In another embodiment of the invention, the fusion protein further comprises an additional linker between the APC-binding domain or the CD91 receptor-binding domain and the translocation peptide, the additional linker comprising SEQ ID NO: 15.
In another embodiment of the invention, the protein transduction domain comprises the sequence of SEQ ID NO: 30.
In another embodiment of the invention, the T cell sensitizing signal-transducing peptide comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 1 or 2.
In another embodiment of the invention, the T cell sensitizing signal-transducing peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1 and 2.
In another embodiment of the invention, the translocation peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 3, 20, 4, and 41.
In another embodiment of the invention, the translocation peptide has 34-61 amino acid residues in length.
In another embodiment of the invention, the protein transduction domain of the fusion protein as aforementioned possesses the following features: (i) the T cell-sensitizing signal-transducing peptide comprises the amino acid sequence of SEQ ID NO: 1 or 2; and (ii) the translocation peptide comprises the amino acid sequence that is at least 95% identical to SEQ ID NO: 3.
The T cell sensitizing signal-transducing peptide exhibits a characteristic of eliciting an antibody that recognizes and binds to the amino acid sequence of K1X2E3X4X5Y6P7P8P9Y10 (SEQ ID NO: 32) of CD28 receptor on T cells, wherein X2 is I or L; X4 is V, F or A, and X5 is M or L.
The antigen-presenting cell (APC) may be selected from the group consisting of dendritic cells, macrophages, B-cells and monocytes.
In one embodiment of the invention, the cell membrane of the APC comprises a CD91 receptor.
In another embodiment of the invention, the pathogen is at least one selected from the group consisting of Human Papillomavirus (HPV), Porcine Reproductive and Respiratory Syndrome Virus (PRRSV), Human Immuno-deficient Virus (HIV-1), flu virus, dengue virus, Hepatitis C virus (HCV), Hepatitis B virus (HBV) and Porcine Circovirus 2 (PCV2).
In one embodiment of the invention, the antigen of a pathogen is selected from the group consisting of Human Papillomavirus (HPV) E7 protein, Hepatitis B virus (HBV) HBx protein, Hepatitis C virus (HCV) core antigen, Flu virus M2 antigen, and a tumor associated antigen.
In one embodiment of the invention, the HPV E7 protein comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 21.
In another embodiment of the invention, the tumor associated antigen is selected from the group consisting of SSX2, MAGE-A3, NY-ESO-1, iLRP, WT12-281, RNF43 (2-116+696-783), and CEA-NE3.
In another embodiment of the invention, the antigen is HPV E7 antigen comprising an amino acid sequence that is at least 90% identical to the sequence selected from the group consisting of SEQ ID NO: 21 and 22. In a preferred embodiment of the invention, the antigen is HPV E7 antigen comprising an amino acid sequence of SEQ ID NO: 21.
In another embodiment of the invention, the fusion protein further comprises an endoplasmic reticulum retention sequence located at the C-terminus of the fusion protein.
In one embodiment of the invention, the immunogenic protein is a fusion protein comprising the sequence of SEQ ID NO: 54. For example, the immunogenic protein is fusion protein PE407-E7-K3 (SEQ ID NO: 54).
In another embodiment of the invention, the immunogenic protein is a fusion protein comprising the sequence of SEQ ID NO: 55. For example, the immunogenic protein is fusion protein RAP1-CD28convPEt-E7-K3 (SEQ ID NO: 55).
In another embodiment of the invention, the immunogenic protein is a fusion protein comprising:
(a) an antigen-presenting cell (APC)-binding domain or a CD91 receptor-binding domain, located at the N-terminus of the fusion protein:
(b) a translocation peptide of 34-112 amino acid residues in length, comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 3, 4, 20, or 41, located at the C-terminus of the APC-binding domain or the CD91 receptor-binding domain; and
(c) an antigen of a pathogen;
(d) a nuclear export signal, comprising the amino acid sequence of SEQ ID NO: 44; and
(e) an endoplasmic reticulum retention sequence, located at the C-terminus of the fusion protein; wherein the nuclear export signal is located between the antigen and the endoplasmic reticulum retention sequence, or between the translocation peptide and the antigen.
In another embodiment of the invention, the immunogenic protein is a fusion protein comprising:
(a) an antigen-presenting cell (APC)-binding domain or a CD91 receptor-binding domain, located at the N-terminus of the fusion protein:
(b) a translocation peptide of 34-61 amino acid residues in length, comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 3, 20, or 41, located at the C-terminus of the APC-binding domain or the CD91 receptor-binding domain; and
(c) an antigen of a pathogen;
(d) a nuclear export signal, comprising the amino acid sequence of SEQ ID NO: 44; and
(e) an endoplasmic reticulum retention sequence, located at the C-terminus of the fusion protein; wherein the nuclear export signal is located between the antigen and the endoplasmic reticulum retention sequence, or between the translocation peptide and the antigen.
In another embodiment of the invention, the C-terminal amino acid of the SEQ ID NO: 44 is alanine.
In another embodiment of the invention, the nuclear export signal comprises the amino acid sequence of SEQ ID NO: 45.
In another embodiment of the invention, the endoplasmic reticulum retention sequence comprises the amino acid sequence of SEQ ID NO: 14.
In another embodiment of the invention, the nuclear export signal and the ER retention sequence forms a fusion peptide comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 43.
In another embodiment of the invention, the translocation peptide has 34-61 amino acid residues in length.
In another embodiment of the invention, the translocation peptide has 34-46 amino acid residues in length.
In another embodiment of the invention, the APC-binding domain or the CD91 receptor-binding domain is free of the amino acid sequence of Pseudomonas exotoxin A (PE) binding domain Ia.
In another embodiment of the invention, the APC-binding domain or the CD91 receptor-binding domain comprises the amino acid sequence of SEQ ID NO: 5.
In another embodiment of the invention, the amino acid sequence of the APC-binding domain or the CD91 receptor-binding domain is SEQ ID NO: 9.
In another embodiment of the invention, the antigen is a fusion antigen of two or more antigenic peptides from a pathogen.
In another embodiment of the invention, the ER retention sequence has more than 4 amino acid residues in length.
In another embodiment of the invention, the translocation peptide comprises an amino acid sequence that is at least 95% identical to SEQ ID NO: 3, 4, 20, or 41.
In another embodiment of the invention, the APC-binding domain or the CD91 receptor-binding domain exhibits a characteristics of recognizing and binding to a receptor on an antigen-presenting cell (APC) selected from the group consisting of dendritic cells, monocytes, B-cells and lymphocytes.
In another embodiment of the invention, the pathogen is selected from the group consisting of Porcine reproductive and respiratory syndrome virus (PRRSV), Porcine Circovirus 2 (PCV2), Foot-and-mouth disease virus (FMDV), Classical Swine Fever Virus (CSFV), Newcastle disease virus (NDV), Transmissible gastroenteritis virus (TGEV), Porcine epidemic diarrhea virus (PEDV), Influenza virus, Pseudorabies virus, Parvovirus, Pseudorabies virus, Swine vesicular disease virus (SVDV), Poxvirus, Rotavirus, Mycoplasma pneumonia, Herpes virus, Infectious bronchitis, and Infectious bursal disease virus.
The composition may be in a dosage form for parenteral, such as for subcutaneous or intramuscular injection.
In another aspect, the invention relates to use of the composition as aforementioned in the manufacture of a medicament for inducing enhanced antigen-specific T cell-mediated immune responses in a subject in need thereof.
Alternatively, in another aspect, the invention relates to the composition as aforementioned for use in inducing enhanced antigen-specific T cell-mediated immune responses in a subject in need thereof.
Further alternatively, the invention relates to a method of inducing enhanced antigen-specific T cell-mediated immune responses in a subject in need thereof comprising administering the subject in need thereof a therapeutically effective amount of the composition as aforementioned and thereby inducing enhanced antigen-specific T cell-mediated immune responses in a subject in need thereof.
These and other aspects will become apparent from the following description of the preferred embodiment taken in conjunction with the following drawings, although variations and modifications therein may be affected without departing from the spirit and scope of the novel concepts of the disclosure.
The accompanying drawings illustrate one or more embodiments of the invention and, together with the written description, serve to explain the principles of the invention. Wherever possible, the same reference numbers are used throughout the drawings to refer to the same or like elements of an embodiment.



BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 shows a schematic drawing of constructs.
FIG. 2 is a table showing cell mediated immunogenicity induced by various vaccine compositions.
FIG. 3 is a table showing humoral immunogenicity induced by various vaccine compositions.
FIG. 4 shows an immunization schedule.
FIG. 5A is a graph showing the interaction of the saponin-base adjuvant GPI-0100 and TLR agonist adjuvant for stimulation of a T cell-mediated immune response elicited by the immunogenic protein PE407-E7-K3.
FIG. 5B shows a graph of the data in FIG. 5A normalized to GPI-0100 (50 μg/dose).
FIG. 6 is a graph showing antibody titers from animal groups of FIG. 5A.
FIG. 7A is a graph showing the interaction of the saponin-base adjuvant QS-21 and TLR agonist adjuvant for stimulation of a T cell-mediated immune response elicited by the immunogenic protein PE407-E7-K3.
FIG. 7B shows a graph of the data in FIG. 7A normalized to QS-21 (10 μg/dose).
FIG. 7C shows a graph of the data in FIG. 7A normalized to GPI-0100 (100 μg/dose).
FIG. 8 is a graph showing antibody titers from animal groups of FIG. 7A.
FIG. 9 is a graph showing a T cell-mediated immune response elicited by various vaccine formulations as indicated.
FIG. 10A is a table showing various vaccine formulations comprising an immunogenic protein and one or two adjuvants.
FIG. 10B shows an immunization schedule in a tumor mouse model.
FIG. 11 is a graph showing tumor size curves from animal groups vaccinated with PE407-E7-K3 in combination with various adjuvants (n=4). The placebo group was treated with PBS (i.e., without adjuvant and PE407-E7-K3).



DETAILED DESCRIPTION OF THE INVENTION
The present invention is more particularly described in the following examples that are intended as illustrative only since numerous modifications and variations therein will be apparent to those skilled in the art. Various embodiments of the invention are now described in detail. Referring to the drawings, like numbers indicate like components throughout the views. As used in the description herein and throughout the claims that follow, the meaning of “a”, “an”, and “the” includes plural reference unless the context clearly dictates otherwise. Also, as used in the description herein and throughout the claims that follow, the meaning of “in” includes “in” and “on” unless the context clearly dictates otherwise. Moreover, titles or subtitles may be used in the specification for the convenience of a reader, which shall have no influence on the scope of the present invention. Additionally, some terms used in this specification are more specifically defined below.
DEFINITIONS
The terms used in this specification generally have their ordinary meanings in the art, within the context of the invention, and in the specific context where each term is used. Certain terms that are used to describe the invention are discussed below, or elsewhere in the specification, to provide additional guidance to the practitioner regarding the description of the invention. For convenience, certain terms may be highlighted, for example using italics and/or quotation marks. The use of highlighting has no influence on the scope and meaning of a term; the scope and meaning of a term is the same, in the same context, whether or not it is highlighted. It will be appreciated that same thing can be said in more than one way. Consequently, alternative language and synonyms may be used for any one or more of the terms discussed herein, nor is any special significance to be placed upon whether or not a term is elaborated or discussed herein. Synonyms for certain terms are provided. A recital of one or more synonyms does not exclude the use of other synonyms. The use of examples anywhere in this specification including examples of any terms discussed herein is illustrative only, and in no way limits the scope and meaning of the invention or of any exemplified term. Likewise, the invention is not limited to various embodiments given in this specification.
Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. In the case of conflict, the present document, including definitions will control.
Immunogenic proteins such as fusion proteins for use as immunogenic enhancers for inducing antigen-specific T cell responses are disclosed in the U.S. Patent No. 20140154285 A1 and 20140154280 A1, each of which is incorporated herein by reference in its entirety.
A Toll like receptor (TLR) 4 ligand, particularly an agonist such as a lipid A derivative particularly monophosphoryl lipid A or more particularly 3 Deacylated monophoshoryl lipid A (3 D-MPL). 3D-MPL is sold under the name MPL by GlaxoSmithKline Biologicals N.A. and is referred throughout the document as MPL or 3D-MPL.
Quil A (derived from the bark of the South American tree Quillaja Saponaria Molina), and fractions thereof are described in U.S. Pat. No. 5,057,540 and “Saponins as vaccine adjuvants”, Kensil, C. R., Crit Rev Ther Drug Carrier Syst, 1996, 12 (1-2):1-55; and EP 0 362 279 B1.
QS-21 is a natural saponin derived from the bark of Quillaja saponaria Molina. QS-21 is a HPLC purified non-toxic fraction of Quil A and it is disclosed in U.S. Pat. No. 5,057,540.
The term “an antigen-presenting cell (APC) or accessory cell” refers to a cell that displays foreign antigens complexed with major histocompatibility complexes (MHC's) on their surfaces. T-cells may recognize these complexes using their T-cell receptors (TCRs). These cells process antigens and present them to T-cells. Main types of professional antigen-presenting cell: dendritic cells (DCs), macrophages, monocytes, and certain B-cells.
The term “an antigen-presenting cell (APC)-binding domain” refers to a domain that can bind to an antigen-presenting cell (APC). The APC-binding domain may be a polypeptide comprising an amino acid sequence that is at least 90% identical to the sequence selected from the group consisting of SEQ ID NOs: 5, 6, 7, 8, and 9. An APC-binding domain is a ligand that recognizes and binds to a receptor on APC.
Cluster of differentiation 91 (CD91) is a protein that forms a receptor in the membrane of cells and is involved in receptor-mediated endocytosis.
The term “a protein transduction domain” refers to a polypeptide or a fusion polypeptide having a function to sensitize T-cells and thus enhance antigen-specific T cell responses, and/or to guide or direct an antigen toward (i.e., to target to) class I major histocompatibility complex (MHC-1) pathway (i.e., a cytotoxic T cell pathway) of antigen presentation.
The term “to sensitize T cells” generally means that CD8+ and CD4+ T cells are sensitized and as a result, CD8+(CTL) and CD4+ T cell responses to an antigen challenge are enhanced. An antigen-specific cell mediated immune response is measured by quantifying the production of antigen-specific induced γ-interferon in response to an antigen. For example, without a sensitization signal (i.e., without the protein transduction domain), an antigen alone may induce weak or no cell mediated immune response at all, i.e., weak or no production of antigen-specific γ-interferon from CD8+ and CD4+ T cells, while in the presence of a sensitization signal (the protein transduction domain), the antigen may induce an enhanced cell mediated immune response. Thus, the function of a sensitization signal (the protein transduction domain) is to sensitize CD4+ and CD8+ T cells in a host so that when the host is later challenged by an antigen, the antigen can induce an enhanced antigen-specific T cell mediated immune response due to prior CD4+ and CD8+ T cell sensitization.
A protein transduction domain may be “a fusion polypeptide”, in which the fusion polypeptide comprises a T cell sensitizing signal-transducing peptide, a linker, and a translocation peptide. For example, the fusion polypeptide may be the polypeptide “CD28convPEt”.
The term “CD28conv” refers to a CD28 conserved region, which is a “T cell sensitizing signal-transducing peptide”. It's an epitope for inducing CD28 agonist antibody.
The term “PEt” or “PEtCore” refers to a PE translocation domain core with 34 amino acid residues in length.
A linker is present between the “CD28conv” and the “PEt”. The orientation or arrangement of the fusion polypeptide “CD28convPEt” is important in that “CD28conv” (or the T cell sensitizing signal-transducing peptide) must be at the upstream to the PEt (or the translocation peptide), i.e., PEt must be at the C-terminus of the “CD28conv” to obtain enhanced T-cell responses. The “CD28convPEt” can raise much higher IgG titer (called CD28-specific agonist antibody) specific to CD28conv than the reversed orientation fusion peptide PEtCD28conv. The CD28-specific agonist antibody can sensitize both CD4+ and CD8+ T cells. The correct orientation fusion polypeptide CD28convPEt contains a linker (R1X2R3X4K5R6) between CD28conv and PEt domains. The linker contains an antigen presenting cell (APC)-specific protease (cathepsin L) cutting site Lys-Arg (KR). Therefore, the fusion protein RAP1-CD28convPEt-Antigen-K3 can be digested into the two fragments: RAP1-CD28conv and PEt-Antigen-K3. The RAP1-CD28conv fragment can be further digested in the lysosome and the epitope of CD28conv is then presented to the APC cell surface via MHC II pathway, which in turn elicits a humoral immune response producing CD28 agonist antibody. Thus, CD28 agonist antibody is produced by B cells. This CD28 agonist antibody can bind to CD28 on the T cell surface and pre-activate the T cells (CD4+ and CD8+ T cells).
A “T cell-sensitizing signal-transducing peptide” has 28-53 amino acid residues in length and comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 31, in which X8 is I or L; X10 is V, F or A. X11 is M or L, X17 is L or I.
The T cell-sensitizing signal-transducing peptide comprises the critical region K1X2E3X4X5Y6P7P8P9Y10 (SEQ ID NO: 32), wherein X2 is I or L; X4 is V, F or A, X5 is M or L.
A T cell sensitizing signal-transducing peptide (TDIYFCKIEFMYPPPYLDNEKSNGTIIH; SEQ ID NO: 31, wherein X8 is L. X10 is F, X11 is M, X17 is L) specific for mice was illustrated in the U.S. Patent No. 20140154285 A1.
A PE translocation peptide may comprise an amino acid sequence that is at least 90% identical to SEQ ID NO: 3, 4, 20 or 41. For example, the amino acid sequence of a PE translocation peptide may be a.a. 280-a.a. 313 (SEQ ID NO: 3), a.a. 268-a.a. 313 (SEQ ID NO: 20), a.a. 253-a.a. 313 (SEQ ID NO: 41), or a.a. 253-a.a. 364 (SEQ ID NO: 4) of full length PE (SEQ ID NO: 10). That is, the amino acid sequence of a PE translocation peptide may contain any region of the PE domain II (a.a. 253 to a.a. 364; SEQ ID NO: 4) as long as it comprises a.a. 280-a.a. 313 (SEQ ID NO: 3) essential fragment.
An antigen may be a pathogenic protein, polypeptide or peptide that is responsible for a disease caused by the pathogen, or is capable of inducing an immunological response in a host infected by the pathogen, or tumor-associated antigen (TAA) which is a polypeptide specifically expressed in tumor cells. The antigen may be selected from a pathogen or cancer cells including, but not limited to, Human Papillomavirus (HPV), Porcine reproductive and respiratory syndrome virus (PRRSV), Human immunodeficiency virus-1 (HIV-1), flu virus, Dengue virus, Hepatitis C virus (HCV), Hepatitis B virus (HBV), Porcine Circovirus 2 (PCV2), Classical Swine Fever Virus (CSFV), Foot-and-mouth disease virus (FMDV), Newcastle disease virus (NDV), Transmissible gastroenteritis virus (TGEV), Porcine epidemic diarrhea virus (PEDV), Influenza virus, Pseudorabies virus, Parvovirus, Pseudorabies virus, Swine vesicular disease virus (SVDV), Poxvirus, Rotavirus, Mycoplasma pneumonia. Herpes virus, infectious bronchitis, or infectious bursal disease virus, non-small cell lung cancer, breast carcinoma, melanoma, lymphomas, colon carcinoma, hepatocellular carcinoma and any combination thereof. For example, HPV E7 protein (E7), HCV core protein (HCV core), HBV X protein (HBx) were selected as antigens for vaccine development. The antigen may be a fusion antigen from a fusion of two or more antigens selected from one or more pathogenic proteins. For example, a fusion antigen of PRRSV ORF6 and ORF5 fragments, or a fusion of antigenic proteins from PRRSV and PCV2 pathogens.
The function of an endoplasmic reticulum retention sequence is to assist translocation of an antigen from an endocytotic compartment into ER and retains it in the lumen. It comprises the sequence Lys Asp Glu Leu (KDEL) or RDEL. An ER retention sequence may comprise, or consists essentially of, or consist of, the sequence of KKDLRDELKDEL (SEQ ID NO: 16), KKDELRDELKDEL (SEQ ID NO: 17), KKDELRVELKDEL (SEQ ID NO: 18), or KDELKDELKDEL (SEQ ID NO: 19).
Receptor-associated protein (RAP1) with a molecular weight of 39 kDa is an ER resident protein and molecular chaperone for LDL receptor-related protein. It has a high binding affinity to CD91 (Kd ̃3 nM) and is composed by three functional-similar domains.
The PE407, (SEQ ID NO. 40) is described in prior patent (U.S. Pat. No. 7,335,361 B2) as PE(ΔIII).
A nuclear export signal (NES) refers to a short amino acid sequence of 4 hydrophobic residues in a protein that targets it for export from the cell nucleus to the cytoplasm through the nuclear pore complex using nuclear transport. The NES is recognized and bound by exportins. The most common spacing of the hydrophobic residues to be L1X2X3K4L5X6X7L8X9L10X11 (SEQ ID NO. 44), where “L” is leucine, “K” is lysine and “X2,3,6,7,9,11” is any naturally occurring amino acid. For example, an artificial NES may comprise the sequence Leu Gin Lys Lys Leu Glu Glu Leu Glu Leu Ala (LQKKLEELELA: SEQ ID NO: 45).
The term “NESK” refers to a fusion peptide of a NES and an ER retention signal (i.e., a NES fused to an ER retention signal). It is an artificial peptide possessing the function of a nuclear export signal (NES) and an ER retention sequence. Thus, it can export an antigen from the cell nucleus to the cytoplasm through the nuclear pore complex, and assist translocation of an antigen from the cytoplasm to ER and retain the antigen in the lumen of the ER. For example, the amino acid sequence of NESK may be LQKKLEELELAKDEL (SEQ ID NO: 43).
The term “subject” refers to a human or a non-human animal.
The term “treating” or “treatment” refers to administration of an effective amount of the fusion protein to a subject in need thereof, who has cancer or infection, or a symptom or predisposition toward such a disease, with the purpose of cure, alleviate, relieve, remedy, ameliorate, or prevent the disease, the symptoms of it, or the predisposition towards it. Such a subject can be identified by a health care professional based on results from any suitable diagnostic method.
The term “an effective amount” refers to the amount of an active compound that is required to confer a therapeutic effect on the treated subject. Effective doses will vary, as recognized by those skilled in the art, depending on rout of administration, excipient usage, and the possibility of co-usage with other therapeutic treatment.
Abbreviations: CD 28, Cluster of Differentiation 28.
EXAMPLES
Without intent to limit the scope of the invention, exemplary instruments, apparatus, methods and their related results according to the embodiments of the present invention are given below. Note that titles or subtitles may be used in the examples for convenience of a reader, which in no way should limit the scope of the invention. Moreover, certain theories are proposed and disclosed herein; however, in no way they, whether they are right or wrong, should limit the scope of the invention so long as the invention is practiced according to the invention without regard for any particular theory or scheme of action.
Immunogenic Protein Preparation:
The immunogenic proteins were expressed in E. coli expression system. They may be antigen itself only, or antigen and a ER retention signal (K3) fused to the C-terminus of Pseudomonas exotoxin A domains I and II (i.e., PE407) to generate PE407-(antigen)-K3 fusion protein or antigen and a ER retention signal fused to the C-terminus of RAP1-CD28convPEt fusion protein to generate RAP1-CD28convPEt-(Antigen)-K3 fusion protein (FIG. 1). The antigen used herein was E7 antigen, and the produced two fusion protein PE407-E7-K3 (SEQ ID NO: 54) and RAP1-CD28convPEt-E7-K3 (SEQ ID NO: 55) were used in the following experiments.
Immunogenicity Analysis of Different Immunogenic Composition:
The E7 immunogenic proteins. E7 antigen, PE407-E7-K3 fusion protein, or RAP1-CD28convPEt-E7-K3 fusion protein were combined with different adjuvant, such as alum, GPI-0100 or QS-21, and their immunogenicity were tested in mice. All immunogenic proteins could elicit medium to strong E7 antigen specific humoral immune response when combined with alum, GPI-0100 or QS-21. For E7 antigen specific cell mediated immune responses, weak to strong responses were elicited when E7 antigen or PE407-E7-K3 fusion protein were combined with GPI-0100 or QS-21. On the other hand, RAP1-CD28convPEt-E7-K3 fusion protein could elicit medium to strong cell mediated immune response when combined with alum, GPI-0100 and QS-21. These results revealed that GPI-0100 and QS-21 were better adjuvants to stimulate both humoral and cell mediated immune responses. Furthermore, PE407-E7-K3 or RAP1-CD28convPEt-E7-K3 fusion protein could elicit stronger responses than E7 antigen only when combined with saponin based adjuvant, such as GPI-0100 or QS-21.
Animal Study for T Cell-Mediated Immune Response Female mice C57BL/6 at 5 weeks old of age were purchased from BioLASCO Taiwan Co., Ltd. 5 mice/cage with a 12 hour day/12 hour night light cycle. Given free access to food and water, the mice were housed for one week and maintained under standard conditions prior to experimentation. The immunogenic protein used for illustration was lyophilized PE407-E7-K3 (SEQ ID NO: 54), which was produced by The Vax Genetics Vaccine Co., Ltd., and each vial contained 0.6 mg protein. Adjuvants: GPI-0100 (Hawaii Biotech); MPL (Cat. No. 699800P, Avanti); Poly I:C (Cat. No. tlrl-pic-5, InvivoGen); R837 (Cat. No. tlrl-imqs, InvivoGen); R848 (Cat. No. tlrl-r848, InvivoGen); CpG1826 (Cat. No. tlrl-1826, InvivoGen); and Laboratory grade QS-21 (TheVax).
The immunization schedule is as shown in FIG. 4. Mice were vaccinated once per week for 3 weeks with vaccine formulations as indicated in Table 1 and FIGS. 5A-B, 7A-C. All mice were sacrificed 7 days after the last immunization, and the spleens were harvested. Splenocytes were isolated.
Adjuvant Formulations
To investigate the best immune response for immunogenic composition, adjuvant formulations listed in Table 1 were evaluated.









TABLE 1









Group II



(TLR agonist adjuvants)












Group I

Imidazolquinoline















(Saponin-base
Poly I:C
MPL
R837
R848
CpG1826


Formulation
adjuvants)
(TLR3
(TLR4
(TLR7
(TLR7/8
(TLR9














No.
QS-21
GPI-0100
agonist)
agonist)
agonist)
agonist)
agonist)











A
Placebo














B

100 μg 







C

50 μg


D


50 μg


E



50 μg


F




50 μg


G





50 μg


H






50 μg


I

50 μg
50 μg


J

50 μg

50 μg


K

50 μg


50 μg


L

50 μg



50 μg


M

50 μg




50 μg


N
10 μg


O


10 μg


P



10 μg


Q




10 μg


R





10 μg


S






10 μg


T
10 μg

10 μg


U
10 μg


10 μg


V
10 μg



10 μg


W
10 μg




10 μg


X
10 μg





10 μg









Intracellular-Cytokine Staining of CD8+ Cells.

Splenocytes (2*107) were plated in 6-well flat-bottom tissue culture plates and incubated for 2 hours at 37° C., and with and without 1 μg/ml HPV16-E7 peptide (amino acids 49-57 of full length PE), and Brefeldin A, and Monensin to increased accumulation of cytokines in the cell enhances the detectability of cytokine-producing cells. After incubation, the cells were transferred to test tube at 300×g for 5 min. The supernatants were discarded, the plates were briefly vortexed, and the cells were stained for surface markers at 0.2 mg/sample of fluorescein isothiocyanate-conjugated anti-mouse CD8 (clone 53-6.7, eBioscience), and anti-mouse CD3 (clone 17A2. BioLegend) for 30 min. The cells were washed with 1 ml of fluorescence-activated cell sorter (FACS) buffer (1% FBS in PBS) and IC Fixation solution (eBioscience) by incubation on ice for 30 min in the dark after resuspension in 1 ml of permeabilization wash buffer (BioLegend). The cells were washed twice in Permwash (BD Pharmingen) and then stained for intracellular IFN-γ with allophycocyanin-conjugated anti-mouse IFN-γ (clone XMG1.2, eBioscience), at 0.2 mg/sample diluted in of permeabilization wash buffer for 30 min on ice in the dark. The cells were resuspension in 1 ml FACS buffer and then analyzed on a FACS Calibur flow cytometer.
In the immunogenicity assays, antigen-specific T cell-mediated immune responses induced by various vaccine formulations were evaluated by measuring the numbers of CD3+/CD8+/IFNγ+ T cells in the splenocytes. FIG. 5A shows percentage of E7-specific CD8+/IFNγ+ double positive in CD3+ T cells per 2*107 splenocytes from animal groups treated with various vaccine formulations. The data from each group were compared against that of the animal group treated with the combination of PE407-K3 and 50 μg/dose of GPI-0100 (FIG. 5B). The data indicated that GPI-0100 in combination with MPL or CpG1826 could potentiate a T cell-mediated immune response elicited by an immunogenic protein for 2-3 folds.
FIG. 7A shows percentage of E7-specific CD8+/IFNγ+ double positive in CD3+ T cells per 2*107 splenocytes from animal groups treated with various vaccine formulations. The data from each group were compared against that of the animal group treated with the combination of PE407-E7-K3 and QS-21 (10 μg/dose; FIG. 7B) or GPI-0100 (100 μg/dose; FIG. 7C). The data indicated that QS-21 in combination with MPL (10 μg/dose) or CpG1826 (10 μg/dose) could potentiate the T cell-mediated immune response elicited by the immunogenic protein PE40-E7-K3 for 3-4 times as compared to the vaccine composition comprising a single adjuvant, QS-21 (10 μg/dose) alone (FIG. 7B). In addition, the T cell-mediated immune response elicited by the vaccine formulation comprising combination adjuvants, QS-21 and MPL, or QS-21 and CpG1826, was 8 times of the animal group treated with the vaccine formulation comprising a single adjuvant. GPI-0100 (100 μg/dose) alone (FIG. 7C).
Humoral Immunity Studies
Animals were vaccinated and the serum samples were collected as described above. The serum samples from each animal and at each collection time point were diluted for 10000 times in blocking buffer. The level of HPV16 E7 specific IgG was detected by ELISA method (coating E7 pet32a 1 μg/well).
FIG. 6 shows that when a single TLR agonist adjuvant was used in the vaccine composition, only a small amount of antibody was induced, but when the TLR agonist adjuvant was used together with the saponin-base adjuvant GPI-0100 (50 μg/dose), a large amount of antibodies were elicited in the mouse after the 3rd immunization.
FIG. 8 shows that when a single TLR agonist adjuvant was used in the vaccine composition, only a small amount of antibody was induced, but when the TLR agonist adjuvant was used together with the saponin-base adjuvant QS-21 (10 μg/dose), the animal groups treated with formulations comprising the two adjuvants QS-21+MPL or QS-21+CpG826 produced a large amount of antibodies after the second immunization (Data not shown). QS-21 in combination with all TLR agonist adjuvants produced a large amount of antibodies after the third immunization. The data shows that combination of QS-21 or GPI-0100 and Poly IC does not potentiate the effect of QS-21 or GPI-0100. This suggests that GPI-100 or QS-21 might operate via a TLR3-related mechanism. Imidazolquline adjuvant (R837, R848) works through the same pathway as CpG1826 but exhibits entirely different T cell-mediated immunity. It remains to be investigated whether midazolquline acts through K cells and/or macrophages cells.
T Cell-Mediated Immunogenic Response Elicited by Fusion Proteins of Different Platforms
We further examines T cell-mediated immunogenic response elicited by different immunogenic proteins PE407-E7-K3 and RAP1-CD28convPEt-E7-K3 using the best combination of adjuvants discovered as described above, and performed the same immunogenicity assays as described in FIG. 5A. Mice 57BL/6 of 5 weeks old age were purchased from BioLASCO Taiwan Co., Ltd. The immunization schedule is as the same as in FIG. 4. Table 2 shows the vaccine formulations used in the studies.
FIG. 9 shows that the fusion protein RAP1-CD28convPEt-E7-K3 elicited a stronger T cell-mediated immune response than the fusion protein PE407-E7-K3. However, no matter what type of combination of adjuvants was used, the two platform elicited a similar pattern of the T cell-mediated immune response.












TABLE 2





Formula-







tion No.
Protein
QS-21
GPI-0100
MPL
CpG1826
















A
Placebo












B
PE407-E7-K3
10 μg
50 μg




C


50 μg


D


50 μg
50 μg


E


50 μg

50 μg


F

10 μg


G

10 μg

10 μg


H

10 μg


10 μg


I
RAP1-
10 μg
50 μg


J
CD28convPEt-

50 μg


K
E7-K3

50 μg
50 μg


L


50 μg

50 μg


M

10 μg


N

10 μg

10 μg


O

10 μg


10 μg









Studies on TC-1 Tumor Animal Model

Vaccine: 100 μg of PE407-E7-K3 is formulated with different adjuvants or combination thereof. Vaccine formulations were shown in FIG. 10A. Seven days after being challenged with TC-1 cell lines (5*104 cell/mouse, s.c.), mice were immunized every 7 days for a total of three times (FIG. 10B). The results indicate that as compared with the single adjuvant GPI-0100 (100 μg/dose) alone, the combination adjuvants QS-21 (10 μg/dose) and MPL (10 μg/dose), QS-21 (10 μg/dose) and CpG1826 (10 μg/dose), GPI-0100 (50 μg/dose) and MPL (50 μg/dose), or GP-0100 (50 μg/dose) and CpG1826 (50 μg/dose) can effectively inhibit the growth of TC-1 tumor cells (FIG. 11).
Table 3 shows SEQ ID NOs. of the components of various fusion proteins.
Table 4 shows the fusion proteins tested for the effects on T cell-mediated immune responses in animals and the sequences of antigens.









TABLE 3







Length


Component
SEQ ID NO:
(residues)

















hCD28 Core
1
28


TDIYFCKIEVMYPPPYLDNEKSNGTIIH




 


hCD28 Maximum
2
53


NCDGKLGNESVTFYLQNLYVNQTDIYFCKIEVMYPPPYLDNE




KSNGTIIHVKG




 


PEt Core (PE translocation domain core; a.a. 280- a.a. 313 of PE)
3
34


 


PEt Maximum (translocation domain maxi, a.a. 253 - a.a. 364 of PE)
4
112


 


RAP1 Minimum (domain III of RAP1)
5
104


 


A2M Minimum
6
153


 


HIV-Tat Minimum
7
24


 


HSPs Minimum,. Heat shock 70 kDa protein (HSPs; Homo sapiens)
8
641


 


Minimum Pseudomonas exotoxin A (PE) binding domain 1a (an
9
252


APC-binding domain, a.a. 1- a.a. 252 of PE)




 


Linker R1X2R3X4K5R6, in which “X2,4” is any amino acid residue.
15
6


 


Full length PE (Exotoxin A mature lbrm, Pseudomonas aeruginosa)
10
613


 


Full length RAP1 (Homo sapiens low density lipoprotein receptor-
11
323


related protein associated protein 1, LRPAP1): Domain 1: a.a. 1-a.a.




112; domain 2: a.a. 113-a.a, 218; domain 3: a.a. 219-aa. 323.




 


Full length A2M (Homo sapiens alpha-2-macroglobulin receptor
12
357


associated protein precursor)




 


HIV-Tat (Human immunodeficiency virus 1)
13
101


 


KDEL (endoplasmic reticulum retention sequence)
14
4


 


KKDLRDELKDEL (K3)
16
12


 


KKDEIRDELKDEL (K3)
17
13


 


KKDELRVELKDEL (K3)
18
13


 


KDELKDELKDEL (K3)
19
12


 


PE268-313(a.a. 268-a.a. 313 of full length PE)
20
46


PLETFTRHRQPRGWEQLEQCGYPVQRLVALYLAARLSWNQV




DQV1R




 


CD28comvPEt
30
68


T1D2I3Y4F5C6K7X8E9X10X11Y12P13P14P15Y16X17D18N19E20K21S22N23




G24T25I26I27H28R29X30R31X32K33R34G35W36E37Q38L39E40Q41C42G43Y44




P45V46Q47R48L49V50A51L52Y53L54A55A56R57L58S59W60N61Q62V63D64Q65




V66I67R68, wherein X8 is I or L; X10 is V, F or A, X11 is M or L, X17




is L or I, X30,32 is any amino acid residue.




 


CD28 consensus sequence
31
28


T1D2I3Y4F5C6K7X8E9X10X11Y12P13P14P15Y16X17




D18N18E20K21S22N23G24T25I26I27H28, wherein X8 is I or L; X10 is V, F




 


CD28 critical region
32
10


K1X2E3X4X5Y6P7P8P9Y10, wherein X2 is I or L; X4 is V, R or A, X5 is




M or L.




 


SSX2
33
187


 


MAGE-A3
34
314


 


NY-ESO-1
35
181


 


iLRP
36
296


 


WT12-281
37
279


 


RNF43(2-116 + 696-783)
38
406


 


CEA-NE3
39
284


 


PE407(a.a. 1-a.a. 407 of full length PE)
40
407


 


PE253-313(a.a. 253-a.a. 313 of full length PE)
41
61


 


PE313(a,a. 1- a.a. 313 of full length PE)
42
313


 


NESK is LQKKLEELELAKDEL *
43
15


 


NES consensus sequence is L1X2X3K4L5X6X7L8X9L10X11, wherein
44
11


“L” is leucine, “K” is lysine and “X2,3,6,7,9,11” is any naturally




occurring amino acid,




 


NES is LQKKLEELELA
45
11


 


PCV2 ORF2 (Porcine Circovirus type 2 Open Reading Frame 2)
46
192


 


CSFV E2 (Classical Swine Fever Virus Envelope glycoprotein E2)
47
328


 


FMDV VP1 peptide (viral capsid protein a.a. 127-a.a. 176 of VP1)
48
50


 


FMDV 3A peptide (a.a. 21-35 of 3A)
49
15


 


FMDV (Foot-and-Mouth Disease Virus) VP1-3A peptide**
50
65


 


NDV F peptide (a.a. 65- a.a. 82 of Fusion protein)
51
18


 


NDV HN peptide (a.a. 101- a.a. 111 of Hemagglutinin-
52
11


Neuraminidase)




 


NDV FHN peptide ***
53
29


 


PE407-E7-K3
54
525


 


RAP1-CD2SconvPEt-E7-K3
55
290





*: The bold letters represents the amino acid sequence of an artificial nuclear exporting signal; the underlined letters represents the amino acid sequence of an endoplasmic reticulum retention signal.


**: The VP1 -3A peptide (SEQ ID NO: 50) is a fusion antigen composed of a.a. 127 - a.a. 176 of VP1 and a.a. 21-a.a. 35 of 3A; i.e., a fusion protein of FMDV VP1 peptide (SEQ ID NO: 48) and FMDV 3A peptide (SEQ ID NO 49).


***: The FHN peptide (SEQ ID NO: 53) is a fusion antigen composed of a.a. 65 - a.a. 82 of fusion protein and (a.a. 101-a.a. 111 at Hemaglutinin-Neuranninidase; i.e., a fusion protein of NDV F peptide (SEQ ID NO: 51) and NDV HN peptide (SEQ ID NO: 52).















TABLE 4







Antigen SEQ


Fusion protein name
Antigen Name
ID NO:







RAP1-CD28convPEt-E7-K3
HPV16 E7 (full length)
21


PE407-E7-K3


RAP1-CD28convPEt-E718-K3
HPV18 E7 (full length)
22


RAP1-CD28convPEt-HCVc-K3
HCV core protein (full length)
23


RAP1-CD28convPEt-HBx-K3
HBV X protein (full length)
24


RAP1-CD28convPEt-PCV2-K3
PCV2 ORF2 (a fragment of ORF2)
25


RAP1-CD28convPEt-DGD-K3
PRRSV nucleocapsid
26



(a fusion antigen: ORF7 a.a. 64-a.a. 123, linker



and ORF7 a.a. 64-a.a. 123)


RAP1-CD28convPEt-M12-K3
PRRSV RNA-dependent RNA polymerase
27



(ORF1b a.a. 1046-a.a. 1210)


RAP1-CD28convPEt-PQAB-K3
PRRSV American strain: a fusion antigen of
28



ORF6 (a.a. 2-a.a. 26) and ORF5 (a.a. 31-a.a. 63)


RAP1-CD28convPEt-RSAB-K3
PRRSV European strain: a fusion antigen of
29



ORF6 (a.a. 2-a.a. 28) and ORF5 (a.a. 31-a.a. 64)









The embodiments and examples were chosen and described in order to explain the principles of the invention and their practical application so as to enable others skilled in the art to utilize the invention and various embodiments and with various modifications as are suited to the particular use contemplated. Alternative embodiments will become apparent to those skilled in the art to which the present invention pertains without departing from its spirit and scope. All references cited and discussed in this specification are incorporated herein by reference in their entireties and to the same extent as if each reference was individually incorporated by reference.

## Claims

1. A composition consisting of:
(a) a therapeutically effective amount of an immunogenic protein;
(b) the saponin-based adjuvant QS21;
(c) a Toll-like receptor (TLR) agonist adjuvant selected from the group consisting of monophosphoryl lipid A (MPL), and CpG oligonucleotide; and
(d) optionally at least one additive selected from the group consisting of mannitol, sucrose, trehalose, histindine, glycine, arginine, sorbitol, Polysorbate 80, glucose, lactose, maltose, maltodextrins, citrate, Tris and sodium phosphate;
wherein the immunogenic protein is a fusion protein comprising:
(a′) an antigen-presenting cell (APC)-binding domain or a CD91 receptor-binding domain, located at the N-terminus of the fusion protein;
(b′) a protein transduction domain, located at the C-terminus of the APC-binding domain or the CD91 receptor-binding domain, the protein transduction domain being selected from the group consisting of:
(i) a fusion polypeptide comprising:
(1) a T cell sensitizing signal-transducing peptide consisting of 28-53 amino acid residues in length, comprising the amino acid sequence of SEQ ID NO: 31, in which Xaa8 is I or L; Xaa10 is V, F or A, Xaa11 is M or L, Xaa17 is L or I, being located at the N-terminus of the fusion polypeptide;
(2) a translocation peptide consisting of 34-112 amino acid residues in length, comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 3, 4, 20, or 41; and
(3) a linker, comprising SEQ ID NO: 15 linking the T cell sensitizing signal-transducing peptide and the translocation peptide;

(ii) a T cell-sensitizing signal-transducing peptide consisting of 28-53 amino acid residues in length, comprising the amino acid sequence of SEQ ID NO: 31, in which Xaa8 is I or L; Xaa10 is V, F or A, Xaa11 is M or L, Xaa17 is L or I; and
(iii) a translocation peptide of 34-112 amino acid residues in length, comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 3, 4, 20 or 41; and

(c′) an antigen of a pathogen, located at the C-terminus of the protein transduction domain.

2. A composition comprising:
(A) a therapeutically effective amount of an immunogenic protein comprising at least an antigen of a pathogen:
(B) the saponin-base adjuvant GPI-0100; and
(C) a Toll-like receptor (TLR) agonist adjuvant selected from the group consisting of monophosphoryl lipid A (MPL), and CpG oligonucleotide, wherein the immunogenic protein is a fusion protein comprising:
(a) an antigen-presenting cell (APC)-binding domain or a CD91 receptor-binding domain, located at the N-terminus of the fusion protein;
(b) a protein transduction domain, located at the C-terminus of the APC-binding domain or the CD91 receptor-binding domain, the protein transduction domain being selected from the group consisting of:
(i) a fusion polypeptide comprising:
(1) a T cell sensitizing signal-transducing peptide consisting of 28-53 amino acid residues in length, comprising the amino acid sequence of SEQ ID NO: 31, in which Xaa8 is I or L; Xaa10 is V, F or A, Xaa11 is M or L, Xaa17 is L or I, being located at the N-terminus of the fusion polypeptide;
(2) a translocation peptide consisting of 34-112 amino acid residues in length, comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 3, 4, 20 or 41; and
(3) a linker, comprising SEQ ID NO: 15 linking the T cell sensitizing signal-transducing peptide and the translocation peptide;

(ii) a T cell-sensitizing signal-transducing peptide consisting of 28-53 amino acid residues in length, comprising the amino acid sequence of SEQ ID NO: 31, in which Xaa8 is I or L; Xaa10 is V, F or A, Xaa11 is M or L, Xaa17 is L or I; and
(iii) a translocation peptide of 34-112 amino acid residues in length, comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 3, 4, 20, or 41; and

(c) an antigen of a pathogen, located at the C-terminus of the protein transduction domain.

3. The composition of claim 2, wherein the protein transduction domain comprises the sequence of SEQ ID NO: 30.

4. The composition of claim 2, wherein the APC-binding domain or the CD91 receptor-binding domain is a polypeptide comprising an amino acid sequence that is at least 90% identical to the sequence selected from the group consisting of SEQ II) NOs: 5, 9, 6, 7, and 8.

5. The composition of claim 2, wherein the T cell sensitizing signal-transducing peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1 and 2.

6. The composition of claim 2, wherein the translocation peptide comprises the amino acid sequence of SEQ ID NO: 3.

7. The composition of claim 2, wherein the pathogen is at least one selected from the group consisting of Human Papillomavirus (HPV), Porcine Reproductive and Respiratory Syndrome Virus (PRRSV), Human Immuno-deficient Virus (HIV-1), flu virus, dengue virus, Hepatitis C virus (HCV), Hepatitis B virus (HBV) and Porcine Circovirus 2 (PCV2).

8. The composition of claim 2, wherein the antigen of a pathogen is selected from the group consisting of Human Papillomavirus (HPV) E7 protein, Hepatitis B virus (HBV) HBx protein, Hepatitis C virus (HCV) core antigen, Flu virus M2 antigen, and a tumor associated antigen.

9. The composition of claim 8, wherein the tumor associated antigen is selected from the group consisting of SSX2, MAGE-A3, NY-ESO-1, iLRP, WT12-281, RNF43 (2-116+696-783), and CEA-NE3.

10. The composition of claim 2, wherein the fusion protein further comprises an endoplasmic reticulum retention sequence located at the C-terminus of the fusion protein.

11. The composition of claim 2, wherein the protein translocation domain is the translocation peptide of 34-112 amino acid residues in length, comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 3, 4, 20, or 41, located at the C-terminus of the APC-binding domain or the CD91 receptor-binding domain; and the fusion protein further comprises
a nuclear export signal, comprising the amino acid sequence of SEQ ID NO: 44; and
an endoplasmic reticulum retention sequence, located at the C-terminus of the fusion protein; wherein the nuclear export signal is located between the antigen and the endoplasmic reticulum retention sequence, or between the translocation peptide and the antigen.

12. The composition of claim 11, wherein the translocation peptide is of 34-61 amino acid residues in length, comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 3, 20, or 41.

13. The composition of claim 2, wherein:
(a) the APC-binding domain or the CD91 receptor-binding domain is a polypeptide comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 9:
(b) the protein transduction domain is the translocation peptide consisting of 34-112 amino acid residues in length, comprising an amino acid sequence that is at least 900/identical to SEQ ID NO: 3, 4, 20 or 41; and
(c) the antigen of a pathogen comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 21.

14. The composition of claim 13, wherein the fusion protein comprises the amino acid sequence of SEQ ID NO: 54.

15. The composition of claim 2, wherein:
(a) the APC-binding domain or the CD91 receptor-binding domain is a polypeptide comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 5;
(b) the protein transduction domain comprises the sequence of SEQ ID NO: 30; and
(c) the antigen of a pathogen comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 21.

16. The composition of claim 15, wherein the fusion protein comprises the amino acid sequence of SEQ ID NO: 55.

17. A method for inducing an enhanced pathogen antigen-specific T cell response, comprising:
administering the composition of claim 2 to a subject in need thereof, and thereby inducing the enhanced pathogen antigen-specific T cell response.

18. A composition consisting of:
(a) a therapeutically effective amount of an immunogenic protein;
(b) the saponin-based adjuvant QS21;
(c) a Toll-like receptor (TLR) agonist adjuvant selected from the group consisting of monophosphoryl lipid A (MPL), and CpG oligonucleotide; and
(d) optionally at least one additive selected from the group consisting of mannitol, sucrose, trehalose, histindine, glycine, arginine, sorbitol, Polysorbate 80, glucose, lactose, maltose, maltodextrins, citrate, Tris and sodium phosphate;
wherein the immunogenic protein is a fusion protein comprising:
(a′) an antigen-presenting cell (APC)-binding domain or a CD91 receptor-binding domain, located at the N-terminus of the fusion protein;
(b′) a translocation peptide of 34-112 amino acid residues in length, comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 3, 4, 20, or 41, located at the C-terminus of the APC-binding domain or the CD91 receptor-binding domain;
(c′) an antigen of a pathogen;
(d′) a nuclear export signal, comprising the amino acid sequence of SEQ ID NO: 44; and
(e′) an endoplasmic reticulum retention sequence, located at the C-terminus of the fusion protein; wherein the nuclear export signal is located between the antigen and the endoplasmic reticulum retention sequence, or between the translocation peptide and the antigen.

19. The composition of claim 18:
wherein the translocation peptide is of 34-61 amino acid residues in length, comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 3, 20, or 41.